<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ocul Biol Dis Infor</journal-id><journal-title-group><journal-title>Journal of Ocular Biology, Diseases, and Informatics</journal-title></journal-title-group><issn pub-type="ppub">1936-8437</issn><issn pub-type="epub">1936-8445</issn><publisher><publisher-name>Humana Press Inc</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20072638</article-id><article-id pub-id-type="pmc">2802512</article-id><article-id pub-id-type="publisher-id">9013</article-id><article-id pub-id-type="doi">10.1007/s12177-008-9013-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Trier</surname><given-names>Klaus</given-names></name><address><phone>+45-39625663</phone><fax>+45-39625642</fax><email>ktrier@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Munk Ribel-Madsen</surname><given-names>S&#x000f8;ren</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Dongmei</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Br&#x000f8;gger Christensen</surname><given-names>S&#x000f8;ren</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Trier Research Laboratories, Tingskiftevej 6, 2900 Hellerup, Denmark </aff><aff id="Aff2"><label>2</label>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China </aff><aff id="Aff3"><label>3</label>Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>11</month><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>11</month><year>2008</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2008</year></pub-date><volume>1</volume><issue>2-4</issue><fpage>85</fpage><lpage>93</lpage><history><date date-type="received"><day>19</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>22</day><month>9</month><year>2008</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2008</copyright-statement></permissions><abstract xml:lang="en"><p>The adenosine antagonist 7-methylxanthine (7-mx) works against myopia in animal models. In a clinical trial, 68 myopic children (mean age 11.3&#x000a0;years) received either placebo or 7-mx tablets for 12&#x000a0;months. All participants subsequently received 7-mx for another 12&#x000a0;months, after which treatment was stopped. Axial length was measured with Zeiss IOL-Master and cycloplegic refraction with Nikon Retinomax at &#x02212;6, 0, 12, 24, and 36&#x000a0;months. Axial growth was reduced among children treated with 7-mx for 24&#x000a0;months compared with those only treated for the last 12&#x000a0;months. Myopia progression and axial eye growth slowed down in periods with 7-mx treatment, but when the treatment was stopped, both myopia progression and axial eye growth continued with invariable speed. The results indicate that 7-mx reduces eye elongation and myopia progression in childhood myopia. The treatment is safe and without side effects and may be continued until 18&#x02013;20&#x000a0;years of age when myopia progression normally stops.</p></abstract><kwd-group><title>Keywords</title><kwd>7-methylxanthine</kwd><kwd>Adenosine receptor antagonist</kwd><kwd>Myopia</kwd><kwd>Clinical trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Humana Press 2008</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Normally, the axial length of the human eye increases from 17&#x000a0;mm at birth to 24&#x000a0;mm at 14&#x000a0;years of age. From an initial hypermetropia the refraction gradually changes toward emmetropia. It has been hypothesized that a growth-control mechanism exists, which can either accelerate or slow down axial growth in response to defocusing of the retinal image during the period of normal eye growth. Results from experimental myopia in mammals suggest that this mechanism works by regulating the scleral extensibility through complex changes in the synthesis and degradation of extracellular matrix components [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>In myopic children an excessive eye elongation is typically seen from age 6&#x000a0;years until 20&#x000a0;years. The axial length will then be in the range of 24&#x02013;28&#x000a0;mm. Until the age of 14&#x000a0;years, the increase in myopia is approximately linear [<xref ref-type="bibr" rid="CR4">4</xref>], after which a slow deceleration is seen [<xref ref-type="bibr" rid="CR5">5</xref>]. With maturity, an increase in collagen cross-linking occurs [<xref ref-type="bibr" rid="CR6">6</xref>], which probably explains the gradual stabilization of myopia. The myopic eye differs in shape from normal eyes, because the increase in length (0.35&#x000a0;mm per diopter) is greater than the increase in height (0.19&#x000a0;mm per diopter) and width (0.1&#x000a0;mm per diopter), resulting in the characteristic &#x0201c;egg-shape&#x0201d; of highly myopic eyes [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>With increasing axial length there is an increased risk of potentially blinding complications later in life, such as retinal detachment, macular degeneration, or glaucoma. About 23% of all cases of retinal detachment occur in eyes with myopia of more than &#x02212;6 dioptres [<xref ref-type="bibr" rid="CR8">8</xref>]. This underlines the importance of finding an efficient and safe way to prevent excessive axial elongation.</p><p>There is today no treatment that efficiently and without side effects controls the progression of myopia [<xref ref-type="bibr" rid="CR9">9</xref>]. Topically applied muscarine antagonists, like the non-selective antagonist atropine, and the M1 selective antagonist pirenzepine have been shown to reduce myopia progression and axial eye growth [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The mechanism of action of atropine and pirenzepine has not been established, but it is assumed that it is independent of their action on accommodation, and that it may depend on receptors in the retina or the sclera [<xref ref-type="bibr" rid="CR13">13</xref>]. Reduced accommodation and dilation of the pupil, however, remain a problem both with atropine and to a lesser degree with pirenzepine.</p><p>The biomechanical properties of sclera are determined by the contents and organization of proteoglycans and collagen [<xref ref-type="bibr" rid="CR14">14</xref>]. Collagen accounts for about 80% of the dry weight of sclera [<xref ref-type="bibr" rid="CR15">15</xref>]. It is known that plastic deformation (creep) of tissues is directly related to the proportion of small diameter fibrils [<xref ref-type="bibr" rid="CR16">16</xref>]. The diameter of the collagen fibrils in sclera from myopic eyes is reduced compared to normal eyes, as are the contents of collagen and glycosaminoglycans [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Experimental myopia in mammals is accompanied by a decrease in the scleral content of proteoglycans and collagen [<xref ref-type="bibr" rid="CR18">18</xref>], with reverse changes taking place during recovery [<xref ref-type="bibr" rid="CR19">19</xref>]. In mammalian models of high myopia, a thinning of the posterior sclera and an increased number of small diameter collagen fibrils in posterior sclera is found [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Treatment of young rabbits with a metabolite of caffeine and theobromine, 7-methylxanthine (7-mx), increases the thickness of the posterior sclera, increases the content of collagen-related amino acids in posterior sclera, and at the same time increases the diameter of the collagen fibrils in the posterior sclera [<xref ref-type="bibr" rid="CR22">22</xref>]. Recently, 7-mx has been shown to reduce the amount of myopia and eye elongation induced by form deprivation in guinea pigs and to counteract the thinning of posterior sclera and of collagen fibrils induced by form deprivation [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>Theobromine and its metabolite, 7-mx, both have very low toxicity [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] and no carcinogenic effects [<xref ref-type="bibr" rid="CR26">26</xref>]. The aim of this study was to test whether 7-mx is useful against axial elongation and myopia progression in childhood myopia.</p></sec><sec id="Sec2"><title>Subjects and methods</title><sec id="Sec3"><title>Participants</title><p>One hundred seven children, aged 8&#x02013;13&#x000a0;years, with a minimum myopia of &#x02212;0.75&#x000a0;diopters (cycloplegic) in one eye were screened using two subject visits with an average interval of 6&#x000a0;months. Eighty-three were found to have an average axial growth rate of 0.075&#x02013;0.39&#x000a0;mm per 6&#x000a0;months, and were enrolled in the study. The low cut-off was chosen in order to exclude children with a normal or close to normal axial growth rate. The high cut-off was chosen in order to exclude atypical cases with an extremely fast progression. The normal axial growth rate in children of this age-group is around 0.05&#x000a0;mm per 6&#x000a0;months [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>All participants were Danish. Children using soft contact lenses were accepted. All children used single vision lenses. The degree of under-correction was not assessed, but the parents were encouraged to have the children&#x02019;s correction adjusted at regular intervals.</p><p>The study followed the tenets of the Declaration of Helsinki. Informed consent was obtained from the participants and their parents. Approval was obtained from the Danish Medicines Agency and the Ethics Committee for the municipality of Copenhagen and Frederiksberg. The trial was registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>, Reg.NCT00263471.</p></sec><sec id="Sec4"><title>Intervention</title><p>During a 12-months placebo-controlled trial, participants received one tablet every morning. The tablets had a diameter of 12&#x000a0;mm and a thickness of 3&#x000a0;mm. Active tablets contained 400&#x000a0;mg 7-mx, placebo tablets only standard filling and binding substances.</p><p>Peak serum concentration after an oral dose of 400&#x000a0;mg 7-mx in adults is around 20&#x000a0;&#x000b5;mol/l with a half-life of 200&#x000a0;min (unpublished results, SM Ribel-Madsen &#x00026; K Trier, 2004). In the rabbit experiment mentioned above [<xref ref-type="bibr" rid="CR22">22</xref>], peak serum level of 7-mx was around 70&#x000a0;&#x000b5;mol/l and half-life around 1&#x000a0;h.</p><p>The 7-mx substance was synthesized by Sigma-Aldrich Co. (Fluka works, Buchs, Switzerland). The tablets were manufactured and packed in a pharmacy certified for pharmaceutical production (Glostrup, Denmark). Participants were asked to bring unused tablets at the end of the follow-up period and the remaining tablets were counted.</p></sec><sec id="Sec5"><title>Outcome measures</title><p>The primary outcome measure was axial growth rate. Secondary outcome measure was myopia progression.</p><p>The axial length was monitored with non-contact, partial coherence interferometer (Zeiss IOL-Master) [<xref ref-type="bibr" rid="CR28">28</xref>]. The refraction was measured with an autorefractor (Retinomax, Nikon) 30&#x000a0;min after one drop of 1% cyclopentolate in each eye. In case of astigmatism, half of the astigmatism was added to the sphere. The same Retinomax autorefractor and IOL-Master was used throughout the trial. Measurement stability was confirmed by means of test eyes. Outcome measures were taken four times and the average calculated.</p><p>Weight was measured at base-line, and weight, height, blood pressure, heart rate at the end of the trial, and participants were questioned specifically for CNS, gastrointestinal or cardiopulmonal symptoms.</p></sec><sec id="Sec6"><title>Sample size</title><p>From a pilot trial, a standard deviation of 0.063&#x000a0;mm on axial growth per year was found. The smallest difference in mean value of axial growth not to be overlooked was set to 0.050&#x000a0;mm. With an accepted risk of type I error of 5% and of type II error of 20%, it was calculated that the number of participants needed in each group was 24.</p></sec><sec id="Sec7"><title>Randomization</title><p>For the 12-month placebo-controlled trial, participants were randomized in a 1:1 ratio to receive 7-mx or placebo. The allocation sequence was generated in the pharmacy and sealed and numbered containers consecutively handed out to the participants. Outcomes were assessed unaware of group assignment at Trier Research Laboratories. No participants or investigators became unmasked during the first 12&#x000a0;months of the trial.</p></sec><sec id="Sec8"><title>Statistical methods</title><p>The distribution of demographic data did not deviate substantially from the normal and variances were homogeneous, hence parametric tests were used. For all data on the state and development of myopia was calculated the average of data from each subject&#x02019;s right and left eye, and these average data were subjected to significance tests. The significance of differences between mean values referring to the respective treatment groups was tested with Mann&#x02013;Whitney test, because of inequality of variances of some of the variables. The significance of differences in axial length or myopia progression rates between periods within the same individual was tested with paired Student&#x02019;s <italic>t</italic> test. Correlations were analyzed with Pearson&#x02019;s test and proportions with Fisher&#x02019;s exact test.</p></sec><sec id="Sec9"><title>24-months follow-up</title><p>After completing the 12-month placebo-controlled trial, children from both the placebo and the 7-mx group were given the option of continued treatment with 7-mx 400&#x000a0;mg either once or twice per day for another 12&#x000a0;months.</p></sec><sec id="Sec10"><title>36-months follow-up</title><p>After completing 24-month follow-up, all participants discontinued treatment with 7-mx, and axial growth and myopia progression was followed for another year by measurement at the end of the total of 36&#x000a0;months&#x02019; follow-up.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>12-month placebo-controlled trial</title><p>The 12-month placebo-controlled trial was completed by 77 children.</p><p>The reason for not completing was in no case stated as side effects. Compliance among those completing the 12-month placebo-controlled trial was 89% in the 7-mx group versus 92% in the placebo group. No differences were found as to weight, height, blood pressure, and heart rate. No subjective side effects were reported.</p><p>Axial growth rate during the 12-month placebo treatment period was found to be proportional to base-line level (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). To ensure comparability between the 7-mx and the placebo group, data were therefore compared within two stratification layers, one with a base-line axial growth rate of 0.075&#x02013;0.190&#x000a0;mm per 6&#x000a0;months, including 19 treated with 7-mx and 27 treated with placebo, and the other with a base-line axial growth rate of 0.200&#x02013;0.390&#x000a0;mm per 6&#x000a0;months, including 16 treated with 7-mx and 15 treated with placebo.
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Correlation between axial length growth-rate during the 12-months placebo controlled trial and the observation period before intervention, shown as mean values for right and left eye in each of the participants in the placebo group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01)</p></caption><graphic xlink:href="12177_2008_9013_Fig1_HTML" id="MO1"/></fig></p><p>Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> show axial growth, myopia progression, and change in corneal curvature in the two stratification layers. In both, axial growth was reduced in the 7-mx group compared with the placebo group. The difference was &#x02212;0.055&#x000a0;mm per year (95% Cl &#x02212;0.114 and +0.005&#x000a0;mm per year) for children with a moderate base-line axial growth rate (<italic>p</italic>&#x02009;=&#x02009;0.073), and &#x02212;0.031&#x000a0;mm per year (95% Cl &#x02212;0.150 and +0.087&#x000a0;mm per year) for children with a high base-line growth rate (<italic>p</italic>&#x02009;=&#x02009;0.593).
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Axial growth, myopia progression, and change in corneal curvature during 12-months placebo-controlled trial in children with a moderate axial growth rate at base-line (0.075&#x02013;0.190&#x000a0;mm per 6&#x000a0;months)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#x000a0;</th><th>Age Months</th><th>Base-line myopia Diopters</th><th>Base-line axial length (mm)</th><th>Base-line corneal curvature Diopters</th><th>Base-line axial growth mm per 6&#x000a0;months (SD)</th><th>Axial growth during trial mm per year (SD)</th><th>Base-line myopia progression Diopters per 6&#x000a0;months (SD)</th><th>Myopia progression Diopters per year (SD)</th><th>Base-line change in corneal curvature Diopters per 6&#x000a0;months (SD)</th><th>Change in corneal curvature during trial Diopters per year (SD)</th></tr></thead><tbody><tr><td>7-mx (<italic>n&#x02009;</italic>=&#x02009;19)</td><td>140.8 (14.2)</td><td>&#x02212;3.10 (2.03)</td><td>24.69 (1.23)</td><td>43.44 (1.23)</td><td>0.134 (0.035)</td><td>0.192 (0.100)</td><td>0.276 (0.148)</td><td>0.398 (0.252)</td><td>0.003 (0.082)</td><td>&#x02212;006 (0.126)</td></tr><tr><td>Placebo (<italic>n&#x02009;</italic>=&#x02009;27)</td><td>135.3 (14.5)</td><td>&#x02212;2.70 (1.36)</td><td>24.42 (0.88)</td><td>43.52 (1.52)</td><td>0.135 (0.039)</td><td>0.247 (0.099)</td><td>0.285 (0.168)</td><td>0.506 (0.324)</td><td>0.021 (0.094)</td><td>&#x02212;0.054 (0.089)</td></tr><tr><td><italic>p</italic> value</td><td>0.146</td><td>0.428</td><td>0.351</td><td>0.851</td><td>0.899</td><td>0.073</td><td>0.863</td><td>0.227</td><td>0.503</td><td>0.131</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Axial growth, myopia progression, and change in corneal curvature during 12-months placebo-controlled trial in children with a high axial growth rate at base-line (0.200&#x02013;0.390&#x000a0;mm per 6&#x000a0;months)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#x000a0;</th><th>Age (month)</th><th>Base-line myopia Diopters</th><th>Base-line axial length mm</th><th>Base-line corneal curvature Diopters</th><th>Base-line axial growth mm per 6&#x000a0;months (SD)</th><th>Axial growth during trial mm per year (SD)</th><th>Base-line myopia progression Diopters per 6&#x000a0;months (SD)</th><th>Myopia progression during trial Diopters per year (SD)</th><th>Base-line change in corneal curvature Diopters per 6&#x000a0;months (SD)</th><th>Change in corneal curvature during trial Diopters per year (SD)</th></tr></thead><tbody><tr><td>7-mx (<italic>n</italic>&#x02009;=&#x02009;16)</td><td>129.6 (21.2)</td><td>&#x02212;3.19 (1.94)</td><td>24.57 (1.01)</td><td>43.59 (1.84)</td><td>0.256 (0.052)</td><td>0.349 (0.149)</td><td>0.535 (0.260)</td><td>0.672 (0.321)</td><td>&#x02212;0.018 (0.096)</td><td>0.018 (0.101)</td></tr><tr><td>Placebo (<italic>n</italic>&#x02009;=&#x02009;15)</td><td>122.9 (15.0)</td><td>&#x02212;2.26 (1.23)</td><td>24.73 (0.75)</td><td>42.32 (1.11)</td><td>0.260 (0.053)</td><td>0.380 (0.173)</td><td>0.482 (0.253)</td><td>0.763 (0.562)</td><td>0.040 (0.073)</td><td>&#x02212;0.023 (0.109)</td></tr><tr><td><italic>p</italic> value</td><td>0.292</td><td>0.126</td><td>0.620</td><td>0.028</td><td>0.832</td><td>0.593</td><td>0.567</td><td>0.582</td><td>0.068</td><td>0.283</td></tr></tbody></table></table-wrap></p><p>Also the myopia progression was lower in the 7-mx group of both stratification layers, with a difference of &#x02212;0.108&#x000a0;diopters per year (95% Cl &#x02212;0.288 and +0.070&#x000a0;diopters per year) (<italic>p</italic>&#x02009;=&#x02009;0.227) and &#x02212;0.091&#x000a0;diopters per year (95% Cl &#x02212;0.424 and +0.243&#x000a0;diopters per year)(<italic>p</italic>&#x02009;=&#x02009;0.582), respectively.</p></sec><sec id="Sec13"><title>24-month follow-up</title><p>The 24-month follow-up period was completed by 68 children. The average daily dose of 7-mx taken by each child during the last 12&#x000a0;months of the follow-up ranged from 40&#x02013;706&#x000a0;mg per day, average 444&#x000a0;mg per day. No subjective side effects were reported.</p><p>Axial growth in children with a moderate base-line axial growth rate (<italic>n</italic>&#x02009;=&#x02009;40) treated for 24&#x000a0;months with 7-mx was 0.329&#x000a0;mm (SD 0.143&#x000a0;mm) compared with 0.427&#x000a0;mm (SD 0.193&#x000a0;mm) in the group treated with placebo for the first 12&#x000a0;months and with 7-mx for the last 12&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.048) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The corresponding axial growth for children with a high base-line axial growth (<italic>n</italic>&#x02009;=&#x02009;28) was 0.547&#x000a0;mm (SD 0.212&#x000a0;mm) for the 7-mx group, and 0.584&#x000a0;mm (SD 0.193&#x000a0;mm) for the placebo/7-mx group (<italic>p</italic>&#x02009;=&#x02009;0.667) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Axial growth in children with a base-line axial growth rate of 0.075&#x02013;0.190&#x000a0;mm per 6&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;40). In the period 12&#x02013;24&#x000a0;months, both groups received 7-methylxanthine. The difference at 24&#x000a0;months was &#x02212;0.098&#x000a0;mm (95% Cl &#x02212;0.211 and 0.013&#x000a0;mm, <italic>p</italic>&#x02009;=&#x02009;0.048)</p></caption><graphic xlink:href="12177_2008_9013_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Axial growth in children with a base-line axial growth rate of 0.200&#x02013;0.390&#x000a0;mm per 6&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;28). In the period 12&#x02013;24&#x000a0;months, both groups received 7-methylxanthine. The difference at 24&#x000a0;months was &#x02212;0.037&#x000a0;mm (95% Cl &#x02212;0.195 and 0.120&#x000a0;mm, <italic>p</italic>&#x02009;=&#x02009;0.667)</p></caption><graphic xlink:href="12177_2008_9013_Fig3_HTML" id="MO3"/></fig></p><p>Myopia progression in children with a moderate base-line axial growth rate (<italic>n</italic>&#x02009;=&#x02009;40) treated for 24&#x000a0;months with 7-mx was 0.627&#x000a0;diopters (SD 0.329&#x000a0;diopters) compared with 0.844&#x000a0;diopters (SD 0.450&#x000a0;diopters) in the group treated with placebo for the first 12&#x000a0;months and with 7-mx for the last 12&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.141) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The corresponding myopia progression for children with a high base-line axial growth (<italic>n</italic>&#x02009;=&#x02009;28) was 1.131&#x000a0;diopters (SD 0.443&#x000a0;diopters) for the 7-mx group, and 1.010&#x000a0;diopters (SD 0.549&#x000a0;diopters) for the placebo/7-mx group (<italic>p</italic>&#x02009;=&#x02009;0.667) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).
<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Myopia progression in children with a base-line axial growth rate of 0.075&#x02013;0.190&#x000a0;mm per 6&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;40). In the period 12&#x02013;24&#x000a0;months, both groups received 7-methylxanthine. The difference at 24&#x000a0;months was &#x02212;0.217&#x000a0;diopters (95% Cl &#x02212;0.478 and 0.044&#x000a0;diopters, <italic>p</italic>&#x02009;=&#x02009;0.141)</p></caption><graphic xlink:href="12177_2008_9013_Fig4_HTML" id="MO4"/></fig><fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Myopia progression in children with a base-line axial growth rate of 0.200&#x02013;0.390&#x000a0;mm per 6&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;28). In the period 12&#x02013;24&#x000a0;months, both groups received 7-methylxanthine. The difference at 24&#x000a0;months was 0.121&#x000a0;diopters (95% Cl &#x02212;0.267 and 0.508&#x000a0;diopters, <italic>p</italic>&#x02009;=&#x02009;0.541)</p></caption><graphic xlink:href="12177_2008_9013_Fig5_HTML" id="MO5"/></fig></p><p>Percentage myopia stabilization in the period 12&#x02013;24&#x000a0;months (defined as less than 0.25&#x000a0;diopters myopia progression during the 12&#x000a0;months) is shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Among children treated for the whole 24-month period with 7-mx, 59% of children with a moderate axial growth rate at base-line, and 20% of children with a high axial growth rate at base-line were stable.
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Myopia stabilization in the period 12&#x02013;24&#x000a0;months</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#x000a0;</th><th>Base-line axial growth 0.075&#x02013;0.190&#x000a0;mm per 6&#x000a0;months</th><th>Base&#x02013;line axial growth 0.200&#x02013;0.390&#x000a0;mm per 6&#x000a0;months</th></tr></thead><tbody><tr><td>Placebo 12&#x000a0;months/7-methylxanthine 12&#x000a0;months</td><td char="." align="char">35%</td><td char="." align="char">21%</td></tr><tr><td>7-methylxanthine 24&#x000a0;months</td><td char="." align="char">59%</td><td char="." align="char">21%</td></tr><tr><td><italic>p</italic> value</td><td char="." align="char">0.2</td><td char="." align="char">1.0</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>36-month follow-up</title><p>Sixty-one children completed 36-month follow-up. In both the group treated with 7-mx 0&#x02013;24&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;28) and the group treated with placebo 0&#x02013;12&#x000a0;months and 7-mx 12&#x02013;24&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;33), axial growth rate in the first as well as the second year of treatment was significantly lower compared with the precedent period (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.00001/<italic>p</italic>&#x02009;=&#x02009;0.001, first year and <italic>p</italic>&#x02009;=&#x02009;0.006/<italic>p</italic>&#x02009;=&#x02009;0.001, second year) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a&#x02013;b). The myopia progression rate, on the other hand, only slowed down in periods with 7-mx treatment (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0005/<italic>p</italic>&#x02009;=&#x02009;0.098, first year and <italic>p</italic>&#x02009;=&#x02009;0.013/<italic>p</italic>&#x02009;=&#x02009;0.01, second year) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c&#x02013;d). However, in both groups, axial growth rate (<italic>p</italic>&#x02009;=&#x02009;0.533/<italic>p</italic>&#x02009;=&#x02009;0.179) and myopia progression rate (<italic>p</italic>&#x02009;=&#x02009;0.162/<italic>p</italic>&#x02009;=&#x02009;0.138) after discontinuation of the treatment (third year) did not differ significantly from the precedent period (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a&#x02013;d).
<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p><bold>a</bold>, <bold>b</bold> Axial growth rate before trial, during treatment with 7-mx or placebo in the first year, during treatment with 7-mx in the second year, and after discontinuation of treatment. In the first and second year, axial growth rate is significantly lower than in the precedent period, but in the third year, after discontinuation of treatment, axial growth rate is not different from the precedent year. <bold>c</bold>, <bold>d</bold> Myopia progression rate in the same periods. The myopia progression rate is significantly reduced compared with the precedent period during treatment with 7-mx, but unchanged in periods with placebo treatment or no treatment</p></caption><graphic xlink:href="12177_2008_9013_Fig6_HTML" id="MO6"/></fig></p></sec></sec><sec id="Sec15"><title>Discussion</title><p>In this study, base-line axial growth rate was taken into consideration when comparing inter-group differences in axial growth. The rate of myopia progression is believed to be the most important variate as regards base-line comparability [<xref ref-type="bibr" rid="CR29">29</xref>]. The finding of a significant correlation between axial growth at base-line and axial growth in the first 12&#x000a0;months of the intervention period supports the importance of using the axial growth rate as one of the inclusion criteria in myopia studies. Frequency of contact lens wear was close to equal in the 7-mx group and the placebo group (17% versus 19% during the 12-months trial). Contact lens wear does not seem to affect the growth of the vitreous chamber significantly [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>The degree of under-correction in the participants was not recorded in this trial, and could therefore theoretically be a confounding factor. One study found that under-correction enhances myopia progression [<xref ref-type="bibr" rid="CR31">31</xref>], while another found no effect [<xref ref-type="bibr" rid="CR32">32</xref>]. It is not known whether the axial growth rate is affected by under-correction.</p><p>At 12&#x000a0;months, the lowest axial growth in both stratification layers was found in the 7-mx groups, but the differences were not significant.</p><p>At 24&#x000a0;months, however, a significantly lower axial growth was found in children with a moderate base-line axial growth rate treated for all 24&#x000a0;months with 7-mx compared with those treated with placebo for the first 12&#x000a0;months and 7-mx for the last 12&#x000a0;months (difference 0.098&#x000a0;mm), whereas the difference among children with a high base-line axial growth rate (0.037&#x000a0;mm) was non-significant.</p><p>Children with a high base-line axial growth rate (0.200&#x02013;0.390&#x000a0;mm per 6&#x000a0;months) have a myopia progression of up to 2&#x000a0;diopters per year. Such severely progressing myopia is frequently linked to specific genetic abnormalities, and may therefore represent a sub-group, possibly more refractory to treatment than the majority of myopes.</p><p>Nevertheless, in the second year of the intervention period, average axial growth among children with a high base-line axial growth rate treated for all 24&#x000a0;months with 7-mx, was reduced to 0.22&#x000a0;mm per year from an initial 0.52&#x000a0;mm per year at base-line. This is lower than the expected average axial growth rate of 0.25&#x000a0;mm per year for age-matched Danish myopes, including low-, moderate-, and high-progressors [<xref ref-type="bibr" rid="CR33">33</xref>]. The corresponding myopia progression rate in the second year of the intervention period among children with a high base-line axial growth rate treated for all 24&#x000a0;months with 7-mx was reduced to 0.49&#x000a0;diopters per year from 1.20&#x000a0;diopters per year at base-line. The expected average myopia progression rate for age-matched Danish myopes, including low-, moderate-, and high-progressors is 0.48&#x000a0;diopters per year [<xref ref-type="bibr" rid="CR33">33</xref>]. For children with a moderate axial growth rate at base-line (0.075&#x02013;0.190&#x000a0;mm per 6&#x000a0;months), treated for all 24&#x000a0;months with 7-mx, axial growth rate was reduced to 0.14&#x000a0;mm per year in the second year of treatment from 0.27&#x000a0;mm per year at base-line, and the myopia progression rate to 0.23&#x000a0;diopters per year in the second year of treatment from 0.52&#x000a0;diopters per year at base-line. Thus, in comparison to the average of age-matched Danish myopes, including low-, moderate-, and high-progressors [<xref ref-type="bibr" rid="CR33">33</xref>], both axial growth and myopia progression was reduced by around 50% in the second year of treatment with 7-mx.</p><p>In an unselected material of myopes, the percent with stable myopia increased with age from 14% for 12-year-olds to 63% for 18-year-olds [<xref ref-type="bibr" rid="CR34">34</xref>]. In comparison, our finding of a markedly higher percentage of stable myopia (59% and 21%, moderate and high base-line axial growth rate respectively) in the second year of treatment, further supports that treatment with 7-mx stabilizes myopia.</p><p>In the age interval 11&#x02013;14&#x000a0;years, myopia progression and axial elongation is close to linear [<xref ref-type="bibr" rid="CR14">14</xref>]. A decrease in both myopia progression rate and axial elongation rate during both the first and the second year of treatment with 7-mx is therefore unexpected. The absence of a further reduction of myopia progression and axial elongation in the third year coincides with the discontinuation of treatment and is consistent with the treatment being efficient.</p><p>Methylxanthines in non-toxic doses block adenosine receptors (ADOR) competitively. Adenosine in the concentrations found under physiological conditions activates primarily A1 and A2A adenosine receptors (ADORA1 and ADORA2A) on the cell surface. ADORA1s are widely distributed in the CNS, whereas ADORA2As are found mainly in the dopamine-rich regions of the brain [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>Adenosine has a general homeostatic role in the regulation of cell metabolism, but also a specific neuromodulatory role with ADORA1s having an inhibitory role and ADORA2As having a facilitatory role in the release of neurotransmitters such as dopamine, noradrenalin, acetylcholine, glutamate, and serotonin [<xref ref-type="bibr" rid="CR36">36</xref>]. ADORA1s and ADORA2As have been localized in the ciliary body and the retina and ADORA2As in the retinal pigment epithelium of adult rats [<xref ref-type="bibr" rid="CR37">37</xref>] and humans (unpublished results, Zhongshan Ophthalmic Center). Both ADORA1s and ADORA2As are expressed in human scleral fibroblasts [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Experimental myopia in animals has been linked to changes in retinal dopamine and acetylcholine neurotransmission [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. Both of these neurotransmitters are modulated by ADORs [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. The mechanism by which 7-mx affects eye elongation and myopia progression could therefore theoretically involve modulation of muscarinic acetycholine or dopamine receptors. On the other hand, it is also possible that ADORs are directly involved in the control of eye growth. Because of receptor adaptation, the effects related to blocking of ADOR1s are attenuated during chronic treatment with non-selective ADOR antagonists like 7-mx, whereas effects related to blocking of ADORA2As are unchanged [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>].</p><p>Adenosine liberated from the retina is believed to activate ADORA2s on the retinal pigment epithelium and augment the standing potential (SP) [<xref ref-type="bibr" rid="CR54">54</xref>]. The effect on the SP might therefore give us a measure of the potency of a specific methylxanthine as a blocker of adenosine receptors. The receptor affinity of 7-mx is three to five times higher than theobromine [<xref ref-type="bibr" rid="CR55">55</xref>]. Correspondingly, the light-rise of SP in humans is more reduced by 7-mx than by theobromine (unpublished results, K Trier, 2004). Interestingly, high ametropia in children is associated with retinal electrophysiological abnormalities, a finding consistent with the hypothesis that the retina is involved in the process of emmetropization [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>In conclusion, systemic treatment with 7-mx appears to be efficient in retarding axial elongation and myopia progression among myopic children. The treatment is safe and without side effects, and may be continued until 18&#x02013;20&#x000a0;years of age, when age-related cross-linking of collagen prevents further elongation of the eye.</p></sec></body><back><ack><p>This work was supported by grants from &#x0201c;J&#x000f8;rgen Bagenkop Nielsens Myopi-Fond&#x0201d; and &#x0201c;Generalkonsul Einar H&#x000f8;yvalds Fond&#x0201d;, and by &#x0201c;&#x000d8;jenl&#x000e6;ge Klaus Trier ApS&#x0201d;.</p><p><bold>Ethics approval</bold> Approval of the trial has been obtained from the Danish Medicines Agency and the Ethics Committee for the municipality of Copenhagen and Frederiksberg (KF 02&#x02013;042/03).</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrien</surname><given-names>NA</given-names></name><name><surname>Gentle</surname><given-names>A</given-names></name></person-group><article-title>Role of sclera in the development and pathological complications of myopia</article-title><source>Prog Ret Eye Res</source><year>2003</year><volume>22</volume><fpage>307</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S1350-9462(02)00063-0</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guggenheim</surname><given-names>JA</given-names></name><name><surname>McBrien</surname><given-names>NA</given-names></name></person-group><article-title>Form-deprivation myopia induces activation of scleral matrix metalloproteinase-2 in tree shrew</article-title><source>Invest Ophthalmol Vis Sci</source><year>1996</year><volume>37</volume><fpage>1380</fpage><lpage>1395</lpage><pub-id pub-id-type="pmid">8641841</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobling</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Gentle</surname><given-names>A</given-names></name><etal/></person-group><article-title>Isoform-specific changes in scleral TGF-&#x003b2; expression and the regulation of collagen synthesis during myopia progression</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>18121</fpage><lpage>18126</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400381200</pub-id><pub-id pub-id-type="pmid">14752095</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>LA</given-names></name><name><surname>Mitchell</surname><given-names>GL</given-names></name><name><surname>Mutti</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Comparison of ocular component growth curves among refractive error groups in children</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>2317</fpage><lpage>2327</lpage><pub-id pub-id-type="doi">10.1167/iovs.04-0945</pub-id><pub-id pub-id-type="pmid">15980217</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorn</surname><given-names>F</given-names></name><name><surname>Gwiazda</surname><given-names>J</given-names></name><name><surname>Held</surname><given-names>R</given-names></name></person-group><article-title>Myopia progression is specified by a double exponential growth function</article-title><source>Opt Vis Sci</source><year>2005</year><volume>82</volume><fpage>E286</fpage><pub-id pub-id-type="doi">10.1097/01.OPX.0000159370.66540.34</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baily</surname><given-names>AJ</given-names></name><name><surname>Paul</surname><given-names>RG</given-names></name><name><surname>Knott</surname><given-names>L</given-names></name></person-group><article-title>Mechanisms of maturation and ageing of collagen</article-title><source>Mech Age Dev</source><year>1998</year><volume>106</volume><fpage>1</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/S0047-6374(98)00119-5</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atchison</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>CE</given-names></name><name><surname>Schmid</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Eye shape in emmetropia and myopia</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>3380</fpage><lpage>3386</lpage><pub-id pub-id-type="doi">10.1167/iovs.04-0292</pub-id><pub-id pub-id-type="pmid">15452039</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polkinghorne</surname><given-names>PJ</given-names></name><name><surname>Craig</surname><given-names>JP</given-names></name></person-group><article-title>North New Zealand rhegmatogenous retinal detachment study: epidemiology and risk factors</article-title><source>Clin Exp Ophthalmol</source><year>2004</year><volume>32</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1111/j.1442-9071.2004.00003.x</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saw</surname><given-names>SM</given-names></name><name><surname>Gazzard</surname><given-names>G</given-names></name><name><surname>Au Eong</surname><given-names>KG</given-names></name></person-group><article-title>Myopia: attempts to arrest progression</article-title><source>Br J Ophthalmol</source><year>2002</year><volume>86</volume><fpage>1306</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1136/bjo.86.11.1306</pub-id><pub-id pub-id-type="pmid">12386095</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>DSP</given-names></name><name><surname>Lam</surname><given-names>DSC</given-names></name><name><surname>Chan</surname><given-names>CKM</given-names></name><etal/></person-group><article-title>Topical atropine in retarding myopia progression and axial length growth in children with moderate to severe myopia: A pilot study</article-title><source>Jpn J Ophthalmol</source><year>2007</year><volume>51</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s10384-006-0380-7</pub-id><pub-id pub-id-type="pmid">17295137</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Siatkowski RM, Cotter S, Crockett RS et al Two-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS. 2008;12:332&#x02013;9.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>DTH</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Chua</surname><given-names>WH</given-names></name><etal/></person-group><article-title>One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2004.06.038</pub-id><pub-id pub-id-type="pmid">15629825</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>GC</given-names></name><name><surname>Gentle</surname><given-names>A</given-names></name><name><surname>McBrien</surname><given-names>NA</given-names></name></person-group><article-title>Muscarine antagonist control of myopia: A molecular search for the M1 receptor in chicks</article-title><source>Mol Vis</source><year>2004</year><volume>10</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">15525903</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>JE</given-names></name></person-group><source>Dermatan Sulphate Proteoglycans</source><year>1993</year><publisher-loc>London</publisher-loc><publisher-name>Portland Press</publisher-name></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>AJ</given-names></name></person-group><article-title>Structure, function and ageing of the collagens of the eye</article-title><source>Eye</source><year>1987</year><volume>1</volume><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">3308525</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parry</surname><given-names>DA</given-names></name></person-group><article-title>The molecular and fibrillar structure of collagen and its relationship to the mechanical properties of connective tissue</article-title><source>Biophys Chem</source><year>1988</year><volume>29</volume><fpage>195</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/0301-4622(88)87039-X</pub-id><pub-id pub-id-type="pmid">3282560</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avetisov</surname><given-names>ES</given-names></name><name><surname>Savitskaya</surname><given-names>NF</given-names></name><name><surname>Vinetskaya</surname><given-names>MI</given-names></name><etal/></person-group><article-title>A study of biochemical and biomechanical properties of normal and myopic eye sclera in humans of different age groups</article-title><source>Metab Pediatr Syst Ophthalmol</source><year>1984</year><volume>7</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">6678372</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rada</surname><given-names>JA</given-names></name><name><surname>Nickla</surname><given-names>DL</given-names></name><name><surname>Troilo</surname><given-names>D</given-names></name></person-group><article-title>Decreased proteoglycan synthesis associated with form deprivation myopia in mature primate eyes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>2050</fpage><lpage>2058</lpage><pub-id pub-id-type="pmid">10892842</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrien</surname><given-names>NA</given-names></name><name><surname>Lawlor</surname><given-names>P</given-names></name><name><surname>Gentle</surname><given-names>A</given-names></name></person-group><article-title>Scleral remodeling in the development and recovery from axial myopia in the tree shrew</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>3713</fpage><lpage>3719</lpage><pub-id pub-id-type="pmid">11053267</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrian</surname><given-names>A</given-names></name><name><surname>Cornell</surname><given-names>LM</given-names></name><name><surname>Gentle</surname><given-names>A</given-names></name></person-group><article-title>Structural and ultrastructural changes to the sclera in a mammalian model of high myopia</article-title><source>Invest Ophthalmol Vis Sci</source><year>2001</year><volume>42</volume><fpage>2179</fpage><lpage>2187</lpage><pub-id pub-id-type="pmid">11527928</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funata</surname><given-names>M</given-names></name><name><surname>Tokoro</surname><given-names>T</given-names></name></person-group><article-title>Scleral changes in experimentally myopic monkeys</article-title><source>Graefe&#x02019;s Arch Clin Exp Ophthalmol</source><year>1990</year><volume>228</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/BF00935729</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trier</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>EB</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide or L-ornithine</article-title><source>Br J Ophthalmol</source><year>1999</year><volume>83</volume><fpage>1370</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1136/bjo.83.12.1370</pub-id><pub-id pub-id-type="pmid">10574816</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Cui D, Trier K, Chen X et al. Effects of 7-methylxanthine on form deprived myopia in guinea pig. In ARVO annual meeting, Ft. Lauderdale, FL; 2008.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarka</surname><given-names>SM</given-names><suffix>Jr</suffix></name></person-group><article-title>The toxicology of cocoa and methylxanthines: a review of the literature</article-title><source>Crit Rev Toxicol</source><year>1982</year><volume>9</volume><fpage>275</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.3109/10408448209037495</pub-id><pub-id pub-id-type="pmid">6765610</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarka</surname><given-names>SM</given-names><suffix>Jr</suffix></name><name><surname>Morrissey</surname><given-names>RP</given-names></name><name><surname>Apgar</surname><given-names>JL</given-names></name></person-group><article-title>Chronic toxicity/carcinogenecity studies of the cocoa powder in rats</article-title><source>Food Chem Toxicol</source><year>1991</year><volume>29</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/0278-6915(91)90057-E</pub-id><pub-id pub-id-type="pmid">1999308</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="book"><source>Monographs on the evaluation of the carcinogenic risk of chemicals to man</source><year>1991</year><publisher-loc>Geneva</publisher-loc><publisher-name>WHO, International Agency for Research on Cancer, 1972-present</publisher-name><fpage>51</fpage><lpage>357</lpage></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zadnik</surname><given-names>K</given-names></name></person-group><article-title>Myopia development in childhood</article-title><source>Optom Vis Sci</source><year>1997</year><volume>74</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1097/00006324-199708000-00021</pub-id><pub-id pub-id-type="pmid">9323731</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carkeet</surname><given-names>A</given-names></name><name><surname>Saw</surname><given-names>SM</given-names></name><name><surname>Gazzard</surname><given-names>G</given-names></name><etal/></person-group><article-title>Repeatability of IOL-Master biometry in children</article-title><source>Optom Vis Sci</source><year>2004</year><volume>81</volume><fpage>829</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1097/01.OPX.0000145020.33250.C0</pub-id><pub-id pub-id-type="pmid">15545808</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoo</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>R</given-names></name></person-group><article-title>Methodologies for interventional myopia studies</article-title><source>Ann Acad Med</source><year>2006</year><volume>35</volume><fpage>282</fpage><lpage>286</lpage></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulk</surname><given-names>GW</given-names></name><name><surname>Cyert</surname><given-names>LA</given-names></name><name><surname>Parker</surname><given-names>DE</given-names></name><etal/></person-group><article-title>The effect of changing from glasses to soft contact lenses on myopia progression in adolescents</article-title><source>Ophthal Physiol Opt</source><year>2003</year><volume>23</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1046/j.1475-1313.2003.00094.x</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>K</given-names></name><name><surname>Mohidin</surname><given-names>N</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>DJ</given-names></name></person-group><article-title>Undercorrection of myopia enhances rather than inhibits myopia progression</article-title><source>Vis Res</source><year>2002</year><volume>42</volume><fpage>2555</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1016/S0042-6989(02)00258-4</pub-id><pub-id pub-id-type="pmid">12445849</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Grice</surname><given-names>K</given-names></name><name><surname>Held</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of spectacle intervention on the progression of myopia in children</article-title><source>Optom Vis Sci</source><year>1999</year><volume>76</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1097/00006324-199906000-00015</pub-id><pub-id pub-id-type="pmid">10416930</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>H</given-names></name></person-group><article-title>Myopia progression in young school children</article-title><source>Acta Ophthalmologica Suppl</source><year>1991</year><volume>69</volume><fpage>1</fpage><lpage>79</lpage></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Dong L, Gwiazda J, Hyman L et al. (2007) Myopia stabilization in the correction of myopia evaluation trial (COMET) cohort. In ARVO annual meeting, Ft. Lauderdale, FL</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredholm</surname><given-names>BB</given-names></name><name><surname>B&#x000e4;ttig</surname><given-names>K</given-names></name><name><surname>Holmen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Actions of caffeine in the brain with special reference to factors that contribute to its widespread use</article-title><source>Pharmacol Rev</source><year>1999</year><volume>51</volume><fpage>83</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">10049999</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>RA</given-names></name></person-group><article-title>Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors</article-title><source>Neurochem Int</source><year>2001</year><volume>38</volume><fpage>107</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/S0197-0186(00)00034-6</pub-id><pub-id pub-id-type="pmid">11137880</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kvanta</surname><given-names>A</given-names></name><name><surname>Seregard</surname><given-names>S</given-names></name><name><surname>Sejersen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Localization of adenosine receptor messenger RNAs in the rat eye</article-title><source>Exp Eye Res</source><year>1997</year><volume>65</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1006/exer.1996.0352</pub-id><pub-id pub-id-type="pmid">9367639</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>D</given-names></name><name><surname>Trier</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Distribution of adenosine receptors in human sclera fibroblasts</article-title><source>Mol Vis</source><year>2008</year><volume>14</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">18385786</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Changes in muscarinic acetylcholine receptor expression in form deprivation myopia in guinea pigs</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>1234</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">17679952</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iuvone</surname><given-names>PM</given-names></name><name><surname>Tigges</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia</article-title><source>Invest Ophthalmol Vis Sci</source><year>1991</year><volume>32</volume><fpage>1674</fpage><lpage>1677</lpage><pub-id pub-id-type="pmid">2016144</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrien</surname><given-names>NA</given-names></name><name><surname>Cottriall</surname><given-names>CL</given-names></name><name><surname>Annies</surname><given-names>R</given-names></name></person-group><article-title>Retinal acetylcholine content in normal and myopic eyes: a role in ocular growth control?</article-title><source>Vis Neurosci</source><year>2001</year><volume>18</volume><fpage>571</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1017/S0952523801184075</pub-id><pub-id pub-id-type="pmid">11829303</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effects of direct intravitreal dopamine injections on the development of lid-suture induced myopia in rabbits</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2006</year><volume>244</volume><fpage>1329</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1007/s00417-006-0254-1</pub-id><pub-id pub-id-type="pmid">16550409</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>CH</given-names></name><name><surname>Chu</surname><given-names>RY</given-names></name><name><surname>Hu</surname><given-names>WZ</given-names></name></person-group><article-title>Effects of pirenzepine on lens-induced myopia in the guinea-pig</article-title><source>Zhonghua Yan Ke Za Zhi</source><year>2003</year><volume>39</volume><fpage>348</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">12895364</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cottriall</surname><given-names>CL</given-names></name><name><surname>McBrien</surname><given-names>NA</given-names></name></person-group><article-title>The M1 muscarinic antagonist pirenzepine reduces myopia and eye enlargement in the tree shrew</article-title><source>Invest Ophthalmol Vis Sci</source><year>1996</year><volume>37</volume><fpage>1368</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">8641840</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>RA</given-names></name></person-group><article-title>Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors</article-title><source>Neurochem Int</source><year>2001</year><volume>38</volume><fpage>107</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/S0197-0186(00)00034-6</pub-id><pub-id pub-id-type="pmid">11137880</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmi</surname><given-names>P</given-names></name><name><surname>Chergui</surname><given-names>K</given-names></name><name><surname>Fredholm</surname><given-names>BB</given-names></name></person-group><article-title>Adenosine-dopamine interactions revealed in knockout mice</article-title><source>J Mol Neurosci</source><year>2005</year><volume>26</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1385/JMN:26:2-3:239</pub-id><pub-id pub-id-type="pmid">16012197</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>L</given-names></name><name><surname>Correia-de-Sa</surname><given-names>P</given-names></name></person-group><article-title>Protein kinase A and Ca(v)1 (L-Type) channels are common targets to facilitatory adenosine A2A and muscarinic M1 receptors on rat motoneurons</article-title><source>Neurosignals</source><year>2005</year><volume>14</volume><fpage>262</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1159/000088642</pub-id><pub-id pub-id-type="pmid">16301841</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>GA</given-names></name><name><surname>Shaffery</surname><given-names>JP</given-names></name><name><surname>Speciale</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Enhancement of rapid eye movement sleep in the rat by actions at A1 and A2a adenosine receptor subtypes with a differential sensitivity to atropine</article-title><source>Neuroscience</source><year>2003</year><volume>116</volume><fpage>913</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00561-4</pub-id><pub-id pub-id-type="pmid">12573729</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yacoubi</surname><given-names>M</given-names></name><name><surname>Ledent</surname><given-names>C</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy</article-title><source>Neuroreport</source><year>2001</year><volume>12</volume><fpage>983</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1097/00001756-200104170-00024</pub-id><pub-id pub-id-type="pmid">11303773</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moo-Puc</surname><given-names>RE</given-names></name><name><surname>G&#x000f3;ngora-Alfaro</surname><given-names>JL</given-names></name><name><surname>Alvarez-Cervera</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy</article-title><source>Neuropharmacology</source><year>2003</year><volume>45</volume><fpage>493</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(03)00202-8</pub-id><pub-id pub-id-type="pmid">12907310</pub-id></mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Daly</surname><given-names>JW</given-names></name></person-group><article-title>Chronic effects of xanthines on levels of central receptors in mice</article-title><source>Cell Mol Neurobiol</source><year>1999</year><volume>19</volume><fpage>719</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1023/A:1006901005925</pub-id><pub-id pub-id-type="pmid">10456233</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>PJ</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name></person-group><article-title>Chronic caffeine treatment causes changes in cardiac Adenosine receptor function in rats</article-title><source>Pharmacology</source><year>2002</year><volume>65</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1159/000058038</pub-id><pub-id pub-id-type="pmid">12037375</pub-id></mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quarta</surname><given-names>D</given-names></name><name><surname>Ferr&#x000e9;</surname><given-names>S</given-names></name><name><surname>Solinas</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>ZB</given-names></name><name><surname>Hockemeyer</surname><given-names>J</given-names></name><name><surname>Popoli</surname><given-names>P</given-names></name><name><surname>Goldberg</surname><given-names>SR</given-names></name></person-group><article-title>Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effect of chronic caffeine exposure</article-title><source>J Neurochem</source><year>2004</year><volume>88</volume><fpage>1151</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.02245.x</pub-id><pub-id pub-id-type="pmid">15009670</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gallemore</surname><given-names>RP</given-names></name><name><surname>Hughes</surname><given-names>BA</given-names></name><name><surname>Miller</surname><given-names>SS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Marmor</surname><given-names>MF</given-names></name><name><surname>Wolfensberger</surname><given-names>TJ</given-names></name></person-group><article-title>Light-induced responses of the retinal pigment epithelium</article-title><source>The retinal pigment epithelium</source><year>1998</year><publisher-loc>New York</publisher-loc><publisher-name>Oxford University Press</publisher-name><fpage>175</fpage><lpage>198</lpage></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>CE</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Manning</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationship at adenosine receptors</article-title><source>J Med Chem</source><year>1993</year><volume>36</volume><fpage>3341</fpage><lpage>3349</lpage><pub-id pub-id-type="doi">10.1021/jm00074a015</pub-id><pub-id pub-id-type="pmid">8230124</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flitcroft</surname><given-names>DI</given-names></name><name><surname>Adams</surname><given-names>GG</given-names></name><name><surname>Robson</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Retinal dysfunction and refractive errors: an electrophysiological study of children</article-title><source>Br J Ophthalmol</source><year>2005</year><volume>89</volume><fpage>484</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1136/bjo.2004.045328</pub-id><pub-id pub-id-type="pmid">15774929</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>Trial registration: ClinicalTrial.gov. Registration number NCT00263471. <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>.</p></fn></fn-group></back></article>